Roots Analysis has announced the addition of “Modular Facilities in Pharmaceutical and Biotechnology Market (3rd Edition), 2023-2035” report to its list of offerings.
Key Market Insights
Presently, over 50 modular facility providers are engaged in the healthcare market, located across the globe
Currently, more than 250 modular cleanroom providers are offering controlled environments along with accessories in the healthcare domain
The partnership activity for modular facilities in healthcare domain has grown at a CAGR of over 30%, in the past three years, 2018-2021
The projected future opportunity for companies engaged in this field is expected to be well distributed across size of facility, type of industry served, type of modular construct, type of construction component, purpose of facility, scale of operation, type of product, type of expansion, type of modular construction, type of material used and key geographical regions.
An insightful competitiveness analysis of players involved in the modular facilities manufacturing in the healthcare domain
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Background
3.3. The Concept of Modular Facilities
3.3.1. Types of Modular Constructs
3.3.2. Modular Construction Process
3.4. Modular Construction in the Pharmaceutical Industry
3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
3.4.2. Modular Pharmaceutical Cleanrooms
3.4.2.1. Cleanroom Classifications and Current Standards
3.4.2.2. Regulations and Standards Concerning Modular Cleanroom Construction
3.5. Advantages of Modular Cleanrooms
3.6. Challenges and Future Prospects
4. MARKET LANDSCAPE: MODULAR FACILITY MANUFACTURERS
4.1. Chapter Overview
4.2. Modular Facility Manufacturers: Overall Market Landscape
4.2.1 Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Year of Establishment and Location of Headquarters
4.2.5. Analysis by Company Size and Location of Headquarters
4.2.6. Analysis by Type of Industry Served
4.2.7. Analysis by Geographical Coverage
4.2.8. Analysis by Type of Industry Served and Geographical Coverage
4.2.9. Analysis by GMP Compliance
4.2.10. Analysis by Geographical Coverage and GMP Compliance
4.2.11. Analysis by Type of Modular Construction
4.2.12. Analysis by Type of Industry Served and Type of Modular Construction
4.2.13. Analysis by Type of Material Used
4.2.14. Analysis by Type of Modular Construction and Type of Material Used
4.2.15. Analysis of Historical and Current Market Landscape Trends
4.2.15.1 Analysis by Company Size, Geographical Coverage and Type of Industry Served
5. MARKET LANDSCAPE: MODULAR CLEANROOM PROVIDERS
5.1. Chapter Overview
5.2. Modular Cleanroom Providers: Overall Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Year of Establishment and Location of Headquarters
5.2.5. Analysis by Company Size and Location of Headquarters
5.2.6. Analysis by Type of Industry Served
5.2.7. Analysis by Location of Headquarters and Type of Industry Served
5.2.8. Analysis by Type of Modular Cleanroom Offered
5.2.9. Analysis by Type of Industry Served and Type of Modular Cleanroom Offered
5.2.10. Analysis by Type of Cleanroom Component Offered
5.2.11. Analysis by Type of Industry Served and Cleanroom Component Offered
5.2.12. Analysis by Type of Modular Cleanroom and Cleanroom Component Offered
5.2.13. Analysis by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom Offered
5.2.14. Analysis by Quality Certifications Obtained
6. MODULAR FACILITY MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS
6.1 Chapter Overview
6.2 Assumptions / Key Parameters
6.3 Methodology
6.4 Company Competitiveness Analysis: Modular Facility Manufacturers
6.4.1. Company Competitiveness Analysis: Benchmarking of Service Strength
6.4.2. Company Competitiveness Analysis: Benchmarking of Partnership activity
6.4.3. Company Competitiveness Analysis: Small Companies
6.4.4. Company Competitiveness Analysis: Mid-Sized Companies
6.4.5. Company Competitiveness Analysis: Large Companies
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Cytiva
7.2.1. Company Overview
7.2.2. Modular Facility-related Services
7.2.3. Modular Projects
7.2.4. Recent Developments and Future Outlook
7.3. G-Con Manufacturing
7.4. Germfree
7.5. IPM Technologies
7.6. KeyPlants
7.7. ModuleCo Pharma
7.8. NNE
7.9. Pharmadule
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Modular Facility Manufacturers: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Product
8.3.5. Analysis by Type of Partnership and Type of Product
8.3.6. Analysis by Type of Modular Facility
8.3.7. Analysis by Type of Product and Type of Modular Facility
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Location of Partner’s Headquarters
8.3.10. Analysis by Location of Modular Facility
8.3.11. Analysis by Type of Partnership and Location of Modular Facility
8.3.12. Analysis by Type of Product and Location of Modular Facility
8.3.13. Intercontinental and Intracontinental Partnerships
8.3.14. Analysis by Country
9. CASE STUDY ON MODULAR PROJECTS IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY
9.1. Chapter Overview
9.2. Modular Facility Projects Undertaken in the Pharmaceutical and Biotechnology Industry
9.3.1. Analysis by Type of Modular Facility
9.3.2. Analysis by Size of Modular Facility
9.3.3. Most Active Manufacturers: Analysis by Number of Projects Delivered
9.3.4. Most Active Clients: Analysis by Number of Projects Received
9.3.5. Analysis by Location of Modular Facility
9.3.6. Analysis by Type of Facility and Size of Modular Facility
9.3.7. Analysis by Client and Location of Facility
10. FACILITY CONSTRUCTION TRENDS IN THE PHARMACEUTICAL INDUSTRY
10.1. Chapter Overview
10.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry: Historical Data for Top 20 Players
10.2.1. Analysis by Number of Facilities Delivered
10.2.2. Analysis by Type of Facility
10.2.3. Analysis by Purpose of Facility
10.2.4. Analysis by Type of Facility and Purpose of Facility
10.2.5. Analysis by Type of Investment
10.2.6. Analysis by Purpose of Facility and Type of Investment
10.2.7. Analysis by Size of Facility
10.2.8. Analysis by Type of Facility and Size of Facility
10.2.9. Analysis by Purpose of Facility and Size of Facility
10.2.10. Analysis by Location of Headquarters
10.2.11. Analysis by Location of Facility
10.2.12. Analysis by Type of Facility and Location of Facility
11. COST-TIME OPTIMIZATION FRAMEWORK
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Factors Influencing Modular Construction
11.3.1. Intrinsic Factors
11.3.2. Extrinsic Factors
11.4. Cost Efficiency Analysis
11.5. Time-Benefit Analysis
11.6. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Modular Facilities Market in the Pharmaceutical / Biotechnology Sector,
2023-2035
12.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Size of Facility, 2023 and 2035
12.4.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Small Facilities, 2023-203
12.4.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Mid-sized Facilities, 2023-2035
12.4.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Large Facilities, 2023-2035
12.4.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Very Large Facilities, 2023-2035
12.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Industry Served, 2023 and 2035
12.5.1. Modular Facilities Market in the Pharmaceutical Industry, 2023-2035
12.5.2. Modular Facilities Market in the Biotechnology Industry, 2023-2035
12.6. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Modular Construct, 2023 and 2035
12.6.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Hybrid Skid Modular Constructs, 2023-2035
12.6.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Skid-Mounted Modular Constructs, 2023-2035
12.6.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Plug-and-Play Modular Constructs, 2023-2035
12.6.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Truckable Modular Constructs, 2023-2035
12.6.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Modular Constructs, 2023-2035
12.7. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Construction Component, 2023 and 2035
12.7.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Process Equipment, 2023-2035
12.7.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Base Buildings, 2023-2035
12.7.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Mechanical, Electrical and Plumbing Systems, 2023-2035
12.7.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Process Commodities, 2023-2035
12.7.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Construction Components, 2023-2035
12.8 Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Purpose of Facility, 2023 and 2035
12.8.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Manufacturing, 2023-2035
12.8.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Aseptic Filling, 2023-2035
12.8.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Research and Development, 2023-2035
12.8.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Purposes, 2023-2035
12.9. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Scale of Operation, 2023 and 2035
12.9.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Clinical Scale, 2023-2035
12.9.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Commercial Scale, 2023-2035
12.10. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Product, 2023 and 2035
12.10.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Cell and Gene Therapies, 2023-2035
12.10.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Vaccines, 2023-2035
12.10.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Biosimilars, 2023-2035
12.10.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Monoclonal Antibodies, 2023-2035
12.10.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Advanced Pharmaceuticals, 2023-2035
12.10.6. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Sterile Products, 2023-2035
12.10.7. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Viral Vectors, 2023-2035
12.10.8. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Products, 2023-2035
12.11. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Facility, 2023 and 2035
12.11.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for New Facilities, 2023-2035
12.11.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Facility Expansions, 2023-2035
12.11.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Planned Expansions, 2023-2035
12.12. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Modular Construction, 2023 and 2035
12.12.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Relocatable Modular Construction, 2023-2035
12.12.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Permanent Modular Construction, 2023-2035
12.13. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Material Used, 2023 and 2035
12.13.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Steel, 2023-2035
12.13.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Wood, 2023-2035
12.13.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Concrete, 2023-2035
12.14. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Geography, 2023 and 2035
12.14.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in North America, 2023-2035
12.14.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Europe, 2023-2035
12.14.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Asia, 2023-2035
12.14.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Middle East and North Africa, 2023-2035
12.14.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Rest of the World,
2023-2035
12.15. Concluding Remaks
13. PREVALENT AND EMERGING INDUSTRY TRENDS
13.1. Chapter Overview
13.2. Adoption of Modular Facilities
13.3. Expansion of Existing Service Portfolio
13.4. Integration of Advanced Technologies
13.4.1. Single-use Technologies
13.4.2. Continuous Processing Technologies
13.4.3. Other Advanced Technologies
14. FUTURE GROWTH OPPORTUNITIES
14.1. Chapter Overview
14.2. Visibility Amongst Start-Ups
14.3. Popularity Amongst Contract Manufacturing Organizations
14.4. Expansion of Existing Facilities
14.5. Adoption for Production of Biosimilars
14.6. Additional Opportunities
14.7. Key Growth Drivers for Modular Construction
14.8. Market Attractiveness in Emerging regions
15. CONCLUSION
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Avon Modular
16.2.2. Interview Transcript: Alan de Zayas (Modular Building Manufacturing and Construction Team)
16.3. Environmental Systems Corporation
16.3.2. Interview Transcript: Vernon Solomon (President)
16.4. Exyte
16.4.2. Interview Transcript: François Abiven (Executive Vice President Global Business Unit BLS) and Luca Mussati (Vice President Technology and Innovation)
16.5. G-Con Manufacturing
16.5.2. Interview Transcript: Maik Jornitz (Chief Executive Officer)
16.6. Modular Devices
16.6.2. Interview Transcript: Mark Koers (Executive Vice President, Sales and Marketing)
16.7. ModWave
16.7.2. Interview Transcript: Pär Almhem (President)
16.8. Subzero Engineering
16.8.2. Interview Transcript: Ward Patton (Director of Sales)
16.9. Vernick
16.9.2. Interview Transcript: Wes Temple (Director of Marketing)
16.10. Zeton
16.10.2. Interview Transcript: Sulogna Roy (Ex-Sales Manager)
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/modular-manufacturing-market/178.html
You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market
Gene Switch Market
You may also like to learn what our experts are sharing in Roots educational series:
Digital Therapies: The “Digital Pills” of current generation
Medical Device Coatings and Modification Technologies
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Posts
Roots Analysis has done a detailed study on “AI-based Digital Pathology Market, 2022-2035”, covering key aspects of the market’s evolution and identifying potential future growth opportunities.
Key Market Insights
Presently, close to 80 players offering AI-based digital pathology services are available in the healthcare market which are located across the globe
In order to tap into the lucrative opportunity associated with AI-based digital pathology, various investment firms have invested over USD 1.7 billion in AI-based digital pathology market space, during the period 2016-2022
The estimated global demand for AI-based digital pathology is expected to grow at a CAGR of 9,4%, during 2022-2035
The projected future opportunity for companies engaged in this field is expected to be well distributed across different types of neural networks, types of assay, end-users, areas of applications, target disease indications, and key geographical regions
Table of Contents
1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Artificial Intelligence in Digital Pathology
3.3. Workflow of AI-based Digital Pathology
3.4. Applications of AI-based Digital Pathology Solutions
3.5. Regulatory Requirements Focused on AI-based Digital Pathology:
3.6. Challenges Associated with the Use of AI in Digital Pathology
3.7. Future Perspectives
4. AI-BASED DIGITAL PATHOLOGY: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. AI-based Digital Pathology Providers: Developers Landscape
4.3. AI-based Digital Pathology Providers: Market Landscape
5. AI-BASED DIGITAL PATHOLOGY MARKET: KEY INSIGHTS
5.1. Chapter Overview
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. PathAI
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook
6.3. Paige
6.4. Akoya Biosciences
6.5. PROSCIA
6.6. Visiopharm
6.7. Roche Tissue Diagnostics
6.8. Aiforia Technologies
6.9. Indica Labs
6.10. Ibex Medical Analytics
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Benchmarking of Portfolio Strength
7.5. Benchmarking of Funding Strength
7.6. Company Competitiveness Analysis: Small Players
7.7. Company Competitiveness Analysis: Mid-sized Players
7.8. Company Competitiveness Analysis: Large Players
8. FUNDING AND INVESTMENTS
8.1. Chapter Overview
8.2. Types of Funding
8.3. AI-based Digital Pathology: List of Funding and Investments
8.4. Concluding Remarks
9. DEMAND ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Global Demand for AI-based Digital Pathology, 2022-2035
9.4. Demand for AI-based Digital Pathology: Analysis by Geography
9.5. Demand for AI-based Digital Pathology: Analysis by Type of End-user
9.6. Concluding Remarks
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global AI-based Digital Pathology Market, 2022-2035
10.4. AI-based Digital Pathology Market: Analysis by Type of Neural Network, 2022 and 2035
10.5. AI-based Digital Pathology Market: Analysis by Type of Assay, 2022 and 2035
10.6. AI-based Digital Pathology Market: Analysis by Type of End-user, 2022 and 2035
10.7. AI-based Digital Pathology Market: Analysis by Area of Application, 2022 and 2035
10.8. AI-based Digital Pathology Market: Analysis by Target Disease Indication, 2022 and 2035
10.9. AI-based Digital Pathology Market: Analysis by Key Geographies, 2022 and 2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. aetherAI
12.3. CTL Clinitech Lab
12.4. Huron Digital Pathology
12.5. Mindpeak
12.6. Pramana
13. APPENDIX 1: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market.html
Learn from experts: do you know about these emerging industry trends?
TIL Therapies: A New Paradigm in Cancer Treatment
Viral Clearance and Viral Testing Services
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The new market report titled “Opportunities in the RNA Therapeutics Market”, published by Roots Analysis is one of the most sought-after solutions for investors operating in the RNA therapeutics market.
The report will help investors stay updated with the latest market trends and opportunities associated with the RNA therapeutics market. The report comes with a concise summary of the details regarding the historical market data, current market trends, future growth prospects, innovator and product landscape, company health indexing, value proposition analysis, company competitiveness, funding and investment, financial analysis of public ventures, business risk analysis, returns on investment and key acquisition targets, as well as the emerging market trends and opportunities in RNA therapeutics market. The opportunities in the RNA therapeutics market are anticipated to expand significantly.
However, the latest report is mainly intended for business leaders, experts, thought leaders, investors, start-ups and growth stage firms interested in RNA Therapeutics business space and is available in the form of PDF and spreadsheet.
Investor Series: Opportunities in the RNA Therapeutics Market:
Investor Series Scope and Market Size:
The report provides detailed information on the RNA therapeutics market, covering the core and peripheral RNA therapeutics solutions. It offers a technical and financial perspective on how the RNA therapeutics market opportunities is likely to evolve, in terms of future business success, over the coming decade. The RNA therapeutics market is broadly segmented on the basis of type of solution, type of therapy, therapeutic area and geographical regions. The segmental growth helps the investors, firms, business leaders to get a lucid picture of the niche pockets of growth, as well as the strategies deployed by the market players to drive the growth of these segments. This section of the report helps them understand and determine the core application areas and the differences between the target markets. The report scrutinizes the RNA therapeutics market in terms of market size & volume and significant information pertaining to product bifurcation and RNA therapeutics solutions overview.
Key Market Contenders:
This particular section of the RNA therapeutics market report covers all the necessary details of the RNA therapeutics’ solutions developed by players operating in the RNA therapeutics market. The report goes on to elucidate a quantitative perspective on the relative health of the different innovator companies and an assessment of the various solutions, offered by the companies developing DTx solutions, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects.
Information on the funding and investment activity that has taken place in this domain since 2011 has also been included in this report. Moreover, the exhaustive report presents financing category-wise trends, describing the relative maturity of the innovator companies. Further, RNA therapeutics market features a list of the leading RNA therapeutics investors , based on their participation in financing activity in this industry segment. It also covers an elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies.
This section of RNA therapeutics market report focusing on the competitive terrain of the RNA therapeutics market endows the reader with every significant detail and information about the leading competitors on the market. The report provides a key acquisition targets analysis, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers and also includes the case study of instances where investors have exited various RNA therapeutics related ventures, offering insights on return on investments made. Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
Section covered in RNA therapeutics market report:
Section 01: Need for RNA Therapeutics and Innovators Landscape
Section 02: Analysis of Investments
Section 03: Financial Analysis and Assessment of Business Risks
Section 04: Market Forecast and Opportunity Analysis
Section 05: Analysis of Returns on Investment and Key Acquisition Targets
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/opportunities-in-RNA-therapeutics-market.html
You may also be interested in the following titles:
Oral Solid Dosage Manufacturing Market
Lipid Nanoparticles in Drug Delivery
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The “Bispecific Antibodies Market report features an in-depth analysis, highlighting the pipeline of various players engaged in this domain.
Roots Analysis has announced the addition of “Bispecific Antibodies Market, 2023-2035” report to its list of offerings.
Key Inclusions
A detailed review of the market landscape of over 220 bispecific antibodies that are either approved or being evaluated in different stages of clinical development, based on several relevant parameters, such as developer company, phase of development, target antigen, type of therapy, route of administration, method of administration, target indication, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer.
An in-depth assessment of the market landscape of over 180 bispecific antibodies that are currently being evaluated in preclinical studies, based on several relevant parameters, such as developer company, stage of development, target antigen, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer.
A detailed assessment of over 80 technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics, featuring a 3-D comparative bubble analyses of bispecific antibody technology platforms based on multiple relevant parameters, such as clinical / preclinical pipeline strength, developer’s years of experience, company size and location of headquarters of developers.
An in-depth analysis of big pharma players engaged in this domain, featuring insightful spider web analyses of such players, based on clinical stage competition, marketed drugs competition, clinical trial activity, partnership activity and technology portfolio strength. Additionally, it features heat map analyses, highlighting the comparison of big pharma players based on various relevant parameters, such as target antigen, antibody format, mechanism of action and target therapeutic area.
Elaborate profiles of prominent drug developers engaged in the development of bispecific antibodies, featuring a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key members of the executive team, financial details / information (if available), drug portfolio, recent developments and an informed future outlook.
An insightful analysis of various partnerships inked between stakeholders engaged within the bispecific antibody therapeutics domain, during the period 2016-2023, based on several relevant parameters, such as year of partnership, type of partnership, disease segment, type of payment model employed, deal amount, most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity.
An in-depth analysis of ongoing and planned studies related to bispecific antibody therapeutics, which were registered till April 2023, taking into consideration several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, type of study, study design, type of sponsor / collaborator, leading industry and non-industry players, key focus areas and geographical location of trials.
A review of different channels used for promoting marketed bispecific antibodies, along with examples of players that have undertaken such initiatives, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies (chosen based on their popularity in this domain), namely Blincyto™ and Hemlibra®, and comparison of both the drugs based on information available on their respective websites.
A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall market.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Therapeutic Area
Autoimmune Disorders
Genetic Disorders
Hematological Malignancies
Ophthalmic Disorders
Skin Cancers
Solid Tumors
Mechanism of Action
Cytokines Retargeting / Neutralization
Dual Ligands Blocking
Resistance Factors Co-targeting
Targeting Tumor Angiogenesis
T-Cell Retargeting / Activation
Others
Target Antigen
C5-Albumin
CD20 x CD3
CD3 x BCMA
CD3 x CD19
EGFR x cMET
EpCAM x CD3
Factor IXa x Factor X
gp100 x CD3
HER2 x HER2
PD-1 x CTLA-4
PD-L1 x TGFβ
TNF-α x HSA
VEGF x DLL4
VEGF-A x ANG2
Antibody Format
Asymmetric
Fragments
Key Players
Akeso Biopharma
Alexion
Amgen
Genmab
Immunocore
Janssen Research & Development
Linton Pharm
Merck
OncXerna Therapeutics
Pfizer
Roche
Taisho Pharmaceutical
Zymeworks
Key Geographical Regions
Asia
Europe
North America
Rest of the World
Key Questions Answered
What is the overall size of the global bispecific antibody therapies market?
What is the rate at which the bispecific antibodies market is likely to grow in the coming years?
Which region has the highest growth rate in the bispecific antibodies market?
Who are the leading players engaged in this market?
How many players are engaged in developing bispecific antibodies?
What are the most common antigens targeted by bispecific antibody therapeutics?
Which target indication covers the largest share in bispecific antibody therapies market?
What is the partnership and collaboration trend in the bispecific antibody therapeutics domain?
What are the upcoming trends in bispecific antibody therapies market?
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
You may also be interested in the following titles:
Medical Device Coatings and Surface Modification Technologies Market
mRNA Synthesis and Manufacturing Services Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has done a detailed study on Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market, covering important aspects of the industry and identifying key future growth opportunities.
Key Market Insights
Presently, more than 70 players across the globe claim to offer deep learning technologies for potential applications across various steps of drug discovery and development process
Majority (70%) of the stakeholders employ proprietary deep learning-based technologies in drug discovery to offer big data analysis
Nearly 50% of the deep learning-based diagnostic providers are based in North America; most such players offer technologies for use across medical imaging and medical diagnosis related applications
Around 70% of the players engaged in offering deep learning solutions for diagnostics have been established post-2011; majority of the players offer solutions focused on oncological disorders
Foreseeing the lucrative potential, a large number of players have made investments worth over USD 15 billion, across 210 funding instances, to advance the initiatives undertaken by industry stakeholders
Over the past few years, more than 704,000 patients have been recruited / enrolled in clinical trials registered for deep learning-based solutions / diagnostics across different geographies
Our proprietary benchmarking analysis, based on a variety of parameters, indicates the leading start-ups / small firms that are spearheading innovation in this domain
Some players have managed to establish strong competitive positions; in the near future, we expect multiple acquisitions to take place wherein the relative valuation of a firm is likely to be a key determinant
Increasing adoption of deep learning technologies in the life sciences and healthcare industry is anticipated to create profitable business opportunities for the technology developers
The market opportunity associated with deep learning in drug discovery is expected to witness an annualized growth rate of 23% over the coming 12 years
In the long term, the opportunity for deep learning in diagnostics is projected to grow exponentially; the market is likely to be well distributed across various therapeutic areas and geographical regions
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Humans, Machines and Intelligence
3.2. The Science of Learning
3.3. The Big Data Revolution
3.4. Deep Learning in Healthcare
3.5. Concluding Remarks
4. MARKET OVERVIEW: DEEP LEARNING IN DRUG DISCOVERY
4.1. Chapter Overview
4.2. Deep Learning in Drug Discovery: Overall Market Landscape of Service / Technology Providers
5. MARKET OVERVIEW: DEEP LEARNING IN DIAGNOSTICS
5.1. Chapter Overview
5.2. Deep Learning in Diagnostics: Overall Market Landscape of Service / Technology Providers
6. COMPANY PROFILES
6.2. Aegicare
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Aiforia Technologies
6.4. Ardigen
6.5. Berg
6.6. Google
6.7. Huawei
6.8. Merative
6.9. Nference
6.10. Nvidia
6.11. Owkin
6.12. Phenomic AI
6.13. Pixel AI
7. PORTER’S FIVE FORCES ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Assumptions
7.3. Key Parameters
7.4. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3 Deep Learning Market: Clinical Trial Analysis
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Deep Learning Market: Funding and Investment Analysis
10. START-UP HEALTH INDEXING
10.1. Chapter Overview
10.2. Start-ups Focused on Deep Learning in Drug Discovery
10.3. Benchmarking Analysis of Start-ups Focused on Deep Learning in Drug Discovery
10.4. Start-ups Focused on Deep Learning in Diagnostics
10.5. Benchmarking Analysis of Start-ups Focused on Deep Learning in Diagnostics
10.5.1. Analysis by Focus Area
11. COMPANY VALUATION ANALYSIS
11.1. Chapter Overview
11.2. Company Valuation Analysis: Key Parameters
11.3. Methodology
11.4. Company Valuation Analysis: Roots Analysis Proprietary Scores
12. MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DRUG DISCOVERY
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Deep Learning in Drug Discovery Market, 2023-2035
13. MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DIAGNOSTICS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Deep Learning in Diagnostics Market, 2023-2035
14. DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS
15. CONCLUDING REMARKS
16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Nucleai
16.3. Mediwhale
16.4. Arterys
16.5. AlgoSurg
16.6. ContextVision
16.7. Advenio Technosys
16.8. Arterys
16.9. Arya.ai
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html
You may also be interested in the following titles:
Decentralized Clinical Trials / Virtual Clinical Trials Market
Exploring AI-based Digital Pathology
Medical Device Coatings Market
Roots Analysis Consulting - the preferred research partner for global firms
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com